Immunome (NASDAQ:IMNM) Shares Up 3.7%

Immunome, Inc. (NASDAQ:IMNM)’s share price was up 3.7% on Wednesday . The stock traded as high as $15.63 and last traded at $15.52. Approximately 134,645 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 787,380 shares. The stock had previously closed at $14.97.

Analyst Ratings Changes

IMNM has been the subject of a number of research analyst reports. Wedbush reiterated an “outperform” rating and issued a $33.00 target price on shares of Immunome in a research report on Tuesday, August 13th. JPMorgan Chase & Co. began coverage on Immunome in a research report on Tuesday, April 30th. They set an “overweight” rating and a $24.00 price objective for the company. Finally, Piper Sandler dropped their price target on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Immunome currently has an average rating of “Buy” and an average target price of $29.00.

Immunome Stock Up 3.7 %

The firm has a 50-day moving average price of $13.59 and a two-hundred day moving average price of $17.20. The company has a market capitalization of $931.32 million, a P/E ratio of -2.06 and a beta of 1.78.

Insider Buying and Selling

In related news, insider Jack Higgins sold 3,524 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total transaction of $49,089.32. Following the transaction, the insider now owns 16,000 shares of the company’s stock, valued at $222,880. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Immunome news, insider Jack Higgins sold 3,524 shares of the business’s stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the sale, the insider now owns 16,000 shares of the company’s stock, valued at approximately $222,880. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jean Jacques Bienaime purchased 7,000 shares of the stock in a transaction on Friday, August 16th. The stock was acquired at an average cost of $13.94 per share, for a total transaction of $97,580.00. Following the acquisition, the director now directly owns 16,615 shares in the company, valued at $231,613.10. The disclosure for this purchase can be found here. 8.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Immunome

Institutional investors and hedge funds have recently bought and sold shares of the business. Quest Partners LLC bought a new stake in shares of Immunome in the 2nd quarter worth about $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Immunome in the 2nd quarter worth about $97,000. Arizona State Retirement System grew its holdings in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares during the last quarter. EntryPoint Capital LLC grew its holdings in shares of Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company’s stock worth $136,000 after purchasing an additional 5,466 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in shares of Immunome in the 4th quarter worth about $172,000. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.